The Radiopharma Infrastructure Blind Spot: Why Investors Keep Missing the Real Bottleneck

Radiopharmaceutical innovation is attracting capital at remarkable speed. The clinical infrastructure required to test that innovation is not scaling at the same rate.

Across the industry, investment is flowing into pipeline acquisitions, radionuclide supply, manufacturing facilities, targeting platforms, and production technologies. Those investments address genuine constraints and reflect growing confidence in radiopharmaceutical medicine.

But every asset eventually reaches the same point: it has to enter the clinic.

That transition depends on a comparatively scarce resource—sites with the people, facilities, licenses, workflows, and capacity to execute radiopharmaceutical trials. For investors assessing the next generation of companies and assets, this radiopharma infrastructure gap deserves greater attention.

Capital Is Following the Science

The scientific rationale for investment is compelling.

Zhang et al. describe a rapidly expanding radiopharmaceutical landscape spanning diagnostic and therapeutic applications, multiple targeting vectors, and radionuclides emitting β-particles, α-particles, Auger electrons, positrons, and gamma radiation.[1] The field has progressed from established targets such as somatostatin receptors and PSMA toward investigational targets including FAP, CXCR4, GRPR, integrins, and others.[1]

That diversity creates new development possibilities, but it also creates different operational requirements. Radionuclide half-life, radiation characteristics, production method, imaging needs, dosimetry, and safety considerations can all influence how a compound moves through clinical development.[1]

A strong radiopharmaceutical industry investment strategy therefore needs to consider more than whether an isotope can be produced or an asset can be manufactured at scale.

It needs to ask whether the clinical system can absorb it.

The Bottleneck Appears at the Site

Radiopharmaceutical trials require capabilities that are not universally available across conventional oncology research sites.

Depending on the protocol, execution may require nuclear medicine expertise, radioactive materials authorization, radiopharmacy capabilities, specialized imaging, radiation safety processes, dosimetry, radioactive waste management, and highly coordinated patient and product scheduling.

These functions also need to operate together.

That distinction matters. A hospital may possess a PET/CT scanner. Another may administer an approved radiopharmaceutical therapy. Neither capability alone establishes readiness to conduct an investigational radiopharmaceutical study.

The Theragnostic Insights brand framework recognizes this translational gap directly, emphasizing site capabilities, radioactive-material regulations, and clinical implementation as central challenges in radiopharmaceutical development.[2]

Theragnostic Insight: A scientifically viable asset and a scalable manufacturing strategy do not guarantee an executable clinical program. Clinical infrastructure is part of development infrastructure.

Capacity Is Harder to Buy Than Equipment

This is where the investment imbalance becomes particularly important.

Manufacturing capacity can be expanded through facilities, partnerships, and capital expenditure. Clinical capacity depends on a more distributed ecosystem.

Experienced nuclear medicine physicians, technologists, radiopharmacists, medical physicists, radiation safety professionals, research coordinators, nurses, and operational teams all contribute to execution. Sites must also accommodate trials alongside existing clinical workloads and competing studies.

Training that workforce takes time. Developing institutional experience takes longer.

The result is a potential mismatch: more radiopharmaceutical assets competing for a clinical network that cannot expand at the same pace.

This is one of the most important Theragnostic development bottlenecks for investors to understand. Clinical capacity may not appear prominently in an asset valuation model, but insufficient capacity can surface later as slower site activation, constrained enrollment, geographic concentration, or difficulty scaling a program across indications.

Clinical Capacity Belongs in Due Diligence

For investors, the practical implication is straightforward: assess the clinical ecosystem alongside the asset.

How many sites can realistically execute the proposed studies? Are those sites already supporting competing radiopharmaceutical programs? Does the radionuclide impose geographic or logistical limits? What specialized personnel are required? Can community sites participate, and what investment would be needed to make them ready?

The answers will differ by program.

An established radioligand using a familiar radionuclide may encounter a different infrastructure environment from an emerging alpha-emitting therapy with specialized handling, dosimetry, or supply requirements. This is why radioligand therapy clinical capacity should be assessed at the asset and protocol level rather than treated as a generic market assumption.

Site availability on paper is not the same as usable capacity.

Rebalancing Investment Toward the Clinic

The industry does not need less investment in manufacturing or isotope supply. It needs a more complete definition of infrastructure.

That includes developing community-site capabilities, investing in workforce training, creating repeatable site-readiness models, integrating operational realities into protocol design, and identifying clinical capacity constraints before they affect enrollment.

For sponsors, these investments can strengthen execution. For healthcare systems, they can create sustainable radiopharmaceutical research capabilities. For investors, they provide a clearer view of whether a company can translate scientific promise into clinical progress.

What This Means for You

Radiopharmaceutical development is entering a period in which capital availability and scientific innovation may no longer be the only factors determining how quickly the field advances.

Clinical capacity could increasingly determine the pace.

Theragnostic Insights works at this intersection—connecting asset strategy with site capability, clinical operations, workforce readiness, and practical implementation.

The next investment question should therefore extend beyond “Can this therapy be made?”

It should include: “Where—and how—will it actually be tested?”

Mini-Series: Clinical Capacity Crisis

The Radiopharma Infrastructure Blind Spot: Why Investors Keep Missing the Real Bottleneck is part of our Clinical Capacity Crisis: The Hidden Bottleneck in Radiopharma Development series, examining how workforce, site capacity, infrastructure, and operational constraints could shape the next phase of radiopharmaceutical growth.

References

[1] Zhang S, Wang X, Gao X, et al., 2025. Radiopharmaceuticals and their applications in medicine. Signal Transduction and Targeted Therapy, 10:1.

[2] Theragnostic Insights. Brand Guidelines V1. Clinical development positioning and radiopharmaceutical site-capability framework.

[3] Society of Nuclear Medicine and Molecular Imaging. Radiopharmaceutical Therapy Centers of Excellence Program. SNMMI.

[4] International Atomic Energy Agency. Nuclear Medicine and Radiopharmaceutical Therapy Resources. IAEA.

‍